Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. - Wikidata - awgldk - TriplyDB

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

http://www.wikidata.org/entity/Q34561392

about

Single dose oral meloxicam for acute postoperative pain in adults Single dose oral meloxicam for acute postoperative pain in adults Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration.The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland Quantitation of meloxicam in the plasma of koalas (Phascolarctos cinereus) by improved high performance liquid chromatography.Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.Hemodynamic and behavioral differences after administration of meloxicam, buprenorphine, or tramadol as analgesics for telemeter implantation in mice Modulator effects of meloxicam against doxorubicin-induced nephrotoxicity in mice.Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus).Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.

P2860

Q24240395-6A08DBA2-5A02-4685-B506-11CC44BB84ED Q24242536-626C4CB4-7AA8-4DFA-9476-3622EBF3CC4D Q28080752-247B1DDE-E998-4E76-A23D-2CF50F3EFBED Q33877752-D8D591CC-B262-40D7-BFCE-03ABD78D51C9 Q34274335-A68B30BF-C9CE-4EFC-8FE3-F64BDFE313F8 Q34327601-CC213E8A-CE4A-4E05-830D-6BEE2C3ABA1C Q35827761-ADB09D50-5ADD-4C71-93C4-74CF43C20099 Q36736592-93B5EED2-5C5F-46E7-9B2E-94BEB327D5BD Q37072046-1685C4F1-7D26-4828-A271-86DDBAE84EC9 Q37201093-B2D840DD-944D-4C03-8F91-12A160B81C38 Q42705756-3197CACC-D3E5-4692-A27B-1E8E975A20D4 Q42785287-E234EE4A-68A9-49F5-8D0B-F4104AEF5699 Q46319583-3869F1A6-9CC1-46A5-9CB2-33C092B0F4A7 Q51125564-CDF43D8D-75E1-4A54-800A-4B893DC7EC7D

P2860

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

http://www.wikidata.org/entity/Q34561392

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@ast

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@en

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@nl

type

label

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@ast

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@en

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@nl

prefLabel

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@ast

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@en

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@nl

P1433

Q34561392-D1462A8C-7F66-465F-973F-A4F3D2D45BF8

P1476

Q34561392-0914043A-DCB1-4CA9-8778-385E9DED730F

P2093

Q34561392-1ACC71EF-B17F-4399-9D86-20501FE23530

Q34561392-32C28FD5-6528-4F49-848A-F24F74ACB333

Q34561392-99ECC46E-2039-4211-85E1-478DAD3596C6

Q34561392-B3170442-3C89-4DAE-8C22-0C01D0732A6E

P2860

Q34561392-03C8A5A1-52D1-4E34-91D3-7699DC8BBF60

Q34561392-16A55F15-6682-4110-8E5C-8FF61C473533

Q34561392-187C8A70-66C4-4578-A9F4-EBEE9F0DE0EC

Q34561392-1BB28A05-2627-4862-BA85-B547A0EB4C86

Q34561392-3654D36B-2A41-42D8-9282-ED6A128E206B

Q34561392-499E3775-F5BE-41F9-B506-5764BE73E743

Q34561392-5A7C0F33-B6C4-4CA9-B618-A3C57FA0F0C6

Q34561392-5CB71D92-206D-47E7-B697-D46BDA76BA24

Q34561392-631A31F7-3893-429A-94C5-5BBD8BFA85C8

Q34561392-67E80446-4740-4956-A412-82D86AC1F3F8

P304

Q34561392-465A3C82-8081-49D5-8879-90D394269869

P31

Q34561392-7A0F0B76-CAA7-456F-89C6-194419B41274

P356

Q34561392-1C4E3020-FBF9-4844-AB35-D3131C1ECA40

P407

Q34561392-99CD9314-EA29-425D-A3DE-030A822349B6

P433

Q34561392-B0A27999-0130-4627-8961-69FBC0BA72B8

P478

Q34561392-D9F1F420-0EE0-46C9-AE91-6EBF650C9816

P577

Q34561392-E61C388D-E2C0-4E72-8CCF-E19B90488821

P698

Q34561392-3CCDD84A-41F1-4376-B587-A2DBD170EE07

P921

Q34561392-343235F9-249C-47EE-941A-84630562B2C7

P356

14656566.6.12.2117

P1433

Expert Opinion on Pharmacotherapy

P1476

Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.

@en

P2093

Brian J Gates

http://www.w3.org/2001/XMLSchema#string

Neal M Davies

http://www.w3.org/2001/XMLSchema#string

Stephen M Setter

http://www.w3.org/2001/XMLSchema#string

Trang T Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib

Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.

Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.

The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study

Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.

Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance.

P304

2117-2140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.6.12.2117

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16197363

http://www.w3.org/2001/XMLSchema#string

P921